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Abstract – A novel metal-chelating system comprising a 4-dimethylamino- 
pyridine and two histidine appendages was synthesized. The two histidines were 
introduced by different manners; one through an amide linkage and other via a 
secondary amino linkage. ESR spectrum suggested a distorted pentacoordinate 
configuration of the copper complex of the ligand. The iron complex of the ligand 
had oxygen-activating property as shown by ESR spin trapping and 
DNA-cleaving activity as evaluated by experiments using pUC19 DNA. 
INTRODUCTION 
DNA-cleaving compounds of natural or artificial origin include a range of metal complexes. Many are 
used as drugs or biological tools owing to their sequence specificity in DNA cleavage.1 A naturally 
occurring cancer chemotherapeutic bleomycin comprises a metal-binding pyrimidine moiety and a 
DNA-recognizing bithiazole.2 The iron complex of bleomycin generates active oxygen species, inducing 
double-strand breaks in DNA.3 We have previously reported artificial chelating ligands based on the 
structure of bleomycin, namely, the amine-type ligand HPH4 and amide-type ligand HPH-Pep5 (Figure 1). 
It was intriguing that the HPH-Fe(II) complex activates molecular oxygen while the HPH-Pep-Fe(II) does 
not. We were interested in hybridizing the structural characteristic of HPH and HPH-Pep to examine 
metal-chelating, oxygen-activating, and DNA-cleaving function. Herein we report such hybridized ligand 
(1) possessing one histidine introduced through an amide bond and other histidine connected by a 
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 secondary amino linkage (Figure 1). 
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Figure 1. Structure of artificial ligands. 
RESULTS AND DISCUSSION 
Ligand (1) was synthesized as shown in Scheme 1. Formyl pyridine derivative (3), prepared in eight steps 
from chelidamic acid (2) according to the procedures previously described6 was treated with trimethyl 
orthoformate in the presence of p-toluenesulfonic acid monohydrate in methanol to afford the dimethyl 
acetal (4) in quantitative yield. Methyl ester (4) was then hydrolyzed and coupled with L-histidine methyl 
ester dihydrochloride (DPPA,7 DMAP in DMF) to give amide (5) in 46% isolated yield. The subsequent 
deacetalization was not straightforward as acetal (5) and aldehyde (6) were inseparable on tlc. 
Deprotection of acetal group was eventually accomplished by heating at 50°C for two days in the 
presence of saturated aqueous tartaric acid and extractive workup afforded crude aldehyde (6). A mixture 
of the crude 6 and L-histidine methyl ester dihydrochloride was stirred in acetonitrile in the presence of 
molecular sieves 3A and triethylamine. The resulting imine was directly hydrogenated with 10% Pd-C to 
afford the ligand (1) in 54% isolated yield.8 
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Scheme 1. Synthesis of ligand (1). 
 
 
 The ESR spectrum of the copper complex of (1) suggested typical pentacoordinate complex in which the 
pyridine nitrogen, the secondary amine nitrogen, the deprotonated peptide nitrogen and the two 
imidazoles bind Cu(II). The configuration seemed distorted pentacoordinated because of relatively small 
A// value (13.5 mT) which is indicative of the stability (Figure 2).9 
 
Figure 2. ESR spectrum of the ligand (1)-Cu(II) complex at 77K. 
 
The oxygen-activating property of the (1)-Fe(II) complex was examined by ESR spin trapping using 
N-tert-butyl-α-phenylnitrone (PBN)10 at room temperature. The sample was carefully prepared under 
argon atmosphere and was kept strictly anaerobic until the oxygen bubbling and the ESR measurement. 
The parameters aN=1.56mT and aH=0.36mT found at g=2.0070 of the observed spectrum are essentially 
identical to these found for the •CH(OH)CH3 adduct of PBN.11 This adduct is presumably formed by the 
reaction of hydroxyl radical with ethanol in the medium, as shown for ethanol in reaction (A). 
•OH + CH3CH2OH → •CH(OH)CH3 + H2O  (A) 
In turn, the carbon centered radicals generated from ethanol and hydroxyl radical, as trapped by 
5,5-dimethyl-1-pyrrolinee N-oxide (DMPO), showed a six-line pattern with aN=2.25mT, aH=1.58mT 
identical to that reported by Johnson.12 In aqueous solution, no additional species such as a 
carbon-centered radical due to the attack of hydroxyl radical was observed. However, the aqueous 
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Figure 3. ESR spin trapping of the ligand (1)-Fe(II)-O2 complex system. (A) 1.0 mM (1) and 
FeBF4•6H2O. (B) 0.2 mM (1) and FeBF4•6H2O. (C) 1.0 mM FeBF4•6H2O. 
 solution of the (1)-Fe(II)-O2 system that does not contain ethanol showed no signal detectable either with 
PBN or with DMPO. It was suggested that the chelate complex was stabilized with ethanol in the medium 
and that hydroxyl radical generated with (1)-Fe(II)-O2 system was trapped with ethanol stabilizing the 
iron complex. In addition, these signal intensity were concentration-dependent (Figure 3). 
 
The DNA-cleaving ability of the (1)-Fe(II) complex was studied by the relaxation of the supercoiled 
pUC19 DNA to the circular DNA and the linear DNA (Figure 4). Control experiments using FeSO4 and 
H2O2 omitting the ligand (1) (lane 1-5) showed DNA cleavage efficiency proportional to the 
concentration of FeSO4. The cleavage efficiency was clearly enhanced in the case of (1)-FeSO4-H2O2 
systems (lane 6-10). 
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Figure 4. Cleavage of supercoiled pUC19 DNA by the Fe(II) complex in a buffer containing 20 mM Tris 
borate buffer in the presence of H2O2 at 37°C. Lane 1-5 : sc pUC19 + 1, 10, 50, 100 and 500 μM 
FeIISO4 + 3.3 mM H2O2 ; Lane 6-10 : sc pUC19 + 1, 10, 50, 100 and 500 μM HPH-M and FeIISO4 + 3.3 
mM H2O2. 
 
Thus, we demonstrated that the new artificial ligand (1) having amino- and amido- linked histidines was 
able to activate molecular oxygen via Fe(II) complex formation as efficiently as the HPH-Fe(II) complex 
and that the (1)-Fe(II)-H2O2 may be useful as a warhead of a DNA-cleaving agent. The effort is 
continuing to assemble a novel DNA-cleaving system based on (1) and specific DNA-recognizing 
molecules. 
EXPERIMENTAL 
Melting point were determined on a Yanagimoto Melting Point Apparatus and were uncorrected. IR 
spectra were recorded on a JASCO IR A-100 Spectrometer. Mass spectra were run on a JEOL 
JMS-DX303HF Mass Spectrometer. 1H and 13C NMR spectra were recorded on a JEOL JNM-AL300. 
ESR spectra were recorded with a JEOL TE200 Spectrometer. 
 
2-(Dimethoxymethyl)-4-(dimethylamino)-6-(methoxycarbonyl)pyridine (4) 
To a solution of 3 (300mg, 1.44mmol) in MeOH (25mL) was added trimethyl orthoformate (0.8mL, 
7.28mmol) and p-toluenesulfonic acid monohydrate (547mg, 2.88mmol). The mixture was refluxed for 
 48 h under argon atmosphere, then concentrated in vacuo. A solution of H2O-saturated aqueous NaHCO3 
(1:1, 25mL) was added and extracted with AcOEt for 3 times. The organic layer was dried over Na2SO4 
and concentrated in vacuo. The residue was chromatographed on silica gel (eluted with n-hexane:AcOEt 
= 1:2) to afford colorless solid 4 (366mg, 100%); mp 80-88 °C; 1H NMR (CDCl3) δ 3.08 (s, 6H), 3.44 (s, 
6H), 3.97 (s, 3H), 5.34 (s, 1H), 6.91 (d, J=2.8Hz, 1H), 7.37 (d, J=2.6Hz); 13C NMR (CDCl3) δ 39.2, 52.7, 
54.3, 105.0, 105.5, 108.3, 147.7, 155.4, 157.9, 166.7; IR (Nujol) 2927, 1709, 1605, 1460, 1377, 1279, 
1191, 1104, 976, 789cm-1; MS (EI) m/z 254 (M++H); HRMS (FAB). Calcd for C12H19N2O4: 255.1345. 
Found: 255.1388.; Anal. Calcd for C12H18N2O4: C, 56.68; H, 7.13; N, 11.02. Found C, 56.63; H, 7.24; N, 
11.02. 
6-(Dimethoxymethyl)-4-(dimethylamino)-2-[[[(S)-2-(1H-imidazol-4-yl)-1-(methoxycarbonyl)ethyl]- 
amino]carbonyl]pyridine (5) 
To a solution of 4 (762mg, 3.00mmol) in MeOH (12mL) was added dropwise 1N aqueous NaOH-MeOH 
(1:1, 12mL) at 0°C. The mixture was stirred for 10 min at 0°C then for 15 min at rt. Water (15mL) was 
added and then MeOH was evaporated in vacuo. The solution was neutralized with 10% aqueous citric 
acid, and the mixture was extracted with CHCl3 for 8 times. The organic layer was dried over Na2SO4 and 
concentrated in vacuo to afford colorless solid. The solid was dissolved in DMF and the solution was 
added L-histidine methyl ester dihydrochloride (870mg, 3.60mmol), diphenylphosphoryl azide (900mg, 
3.30mmol) and 4-dimethylaminopyridine (450mg, 3.60mmol) at 0°C. The mixture was stirred at from 
0°C to rt for 48 h under argon atmosphere, then concentrated in vacuo. The residue was dissolved in 
CHCl3, and the solution was washed with saturated aqueous NaHCO3 and brine. The organic layer was 
dried over Na2SO4 and concentrated in vacuo. The residue was chromatographed on silica gel (eluted 
with CH2Cl2:MeOH = 10:1) to afford yellow oil 5 (537mg, 46%: 2steps from 4); [α]20D -13.5°(c=1.0, 
MeOH); 1H NMR (CDCl3) δ 3.05 (s, 6H), 3.24 (d, J=5.7Hz, 2H), 3.42 (d, J=5.9Hz, 6H), 3.73 (s, 3H), 
4.98 (dt, J=8.1, 5.7Hz, 1H), 5.23 (s, 1H), 6.83 (s, 1H), 6.84 (d, J=2.8Hz, 1H), 7.36 (d, J=2.8Hz, 1H), 7.52 
(d, J=0.9Hz, 1H), 8.81 (d, J=8.1Hz, 1H); 13C NMR (CDCl3) δ 29.6, 39.3, 52.3, 52.5, 53.9, 54.2, 104.6, 
105.1, 105.4, 120.3, 129.6, 135.2, 149.0, 155.8, 156.4, 165.3, 171.9; IR (Nujol) 2924, 2854, 2360, 1748, 
1670, 1607, 1459, 1377, 1061cm-1; MS (FAB) m/z 392 (M+H)+; HRMS (FAB). Calcd for C18H26N5O5: 
392.1934. Found: 392.1993. 
Methyl (S)-2-[(4-Dimethylamino-6-formylpyridine-2-carbonyl)amino]-3-(1H-imidazol-4-yl)propio- 
nate (6) 
A solution of 5 (274mg, 0.70mmol) in saturated aqueous tartaric acid (15mL) was stirred at 50°C, then 
alkalified to pH 8 with aqueous NaHCO3 and extracted with CHCl3 for 5 times. The organic layer was 
dried over Na2SO4 and concentrated in vacuo to give crude 6, which was used without further purification 
(Rf 0.30 [MERCK silica gel 60 F254 developed with CH2Cl2:MeOH =10:1])) (124mg, 52%); 1H NMR 
 (CDCl3) δ 3.09 (s, 6H), 3.27 (d, J=5.5Hz, 2H), 3.74 (s, 3H), 5.02 (dt, J=7.5, 5.5Hz, 1H), 6.86 (s, 1H), 
7.19 (d, J=2.6Hz, 1H), 7.54 (d, J=2.6Hz, 1H), 7.55(s, 1H), 9.10 (d, 7.5Hz, 1H), 9.95 (s, 1H); 13C NMR 
(CDCl3) δ 29.7, 39.5, 52.5. 54.0, 105.4, 108.4, 120.2, 129.7, 135.2, 150.1, 151.9, 155.8, 164.5, 171.9, 
194.0; MS (FAB) m/z 346 (M+H)+ . 
Methyl (S)-3-(1H-imidazol-4-yl)-2-[[[6-[[[(S)-2-(1H-imidazol-4-yl)-1-(methoxycarbonyl)ethyl]- 
amino]carbonyl]-4-(dimethylamino)pyridine-2-yl]methyl]amino]propionate (1) 
To a solution of 6 (86mg, 0.25mmol) and L-histidine methyl ester dihydrochloride (77mg, 0.32mmol) in 
MeCN (30mL) was added molecular sieves 3A (2.5g) and Et3N (0.91mL, 0.62mmol). The mixture was 
stirred at rt for 22 h under argon atmosphere, filtrated on celite, and concentrated in vacuo to give a crude 
product. The residue was dissolved in MeOH. The solution was added palladium-activated carbon (Pd 
10%) (163mg) and stirred at rt for 5 h under hydrogen atmosphere. The mixture was filtrated on celite, 
and concentrated in vacuo. To the residue was  
added saturated aqueous NaHCO3, then the mixture was extracted with CHCl3 for 3 times. The organic 
layer was dried over Na2SO4, and concentrated in vacuo. The residue was chromatographed on NH silica 
gel (eluted with CH2Cl2:MeOH = 20:1) to afford yellow oil 1(67mg, 54%); [α]20D -4.7° (c=1.0, MeOH); 
1H NMR (CDCl3) δ 2.76-3.10 (m, 2H), 2.99 (s, 6H), 3.19 (dd, J=14.9, 5.1Hz, 1H), 3.29 (dd, J=14.9, 
5.1Hz, 1H), 3.64-3.86 (m, 3H), 3.70 (s, 3H), 3.75 (s, 3H), 4.95 (dt, J=7.9, 5.1Hz, 1H), 6.40 (d, J=2.4Hz, 
1H), 6.71 (s, 1H), 6.85 (s, 1H), 7.29 (d, J=2.4Hz, 1H), 7.36 (s, 1H), 7.41 (s, 1H), 8.90 (d, J=7.9Hz, 1H); 
13C NMR (CDCl3) δ 29.6, 30.2, 39.3, 52.0, 52.5, 53.1, 60.6, 61.0, 104.1, 106.8, 116.4, 117.7, 131.6, 133.0, 
135.0, 135.1, 149.2, 155.6, 157.3, 165.2, 172.5, 174.5; IR (Film) 3123, 2952, 1737, 1666, 1608, 1523, 
1437, 1392, 1201, 1021, 833cm-1; MS (FAB) m/z 499 (M+H)+; HRMS (FAB). Calcd for C23H31N8O5: 
499.2417. Found: 499.2473. 
ESR spectra 
Solution of the Cu(II) complexes were prepared by mixing ligand and copper(II) perchlorate hexahydrate 
in methanol. Concentration were 1×10-3 at a molar ratio of Cu:ligand = 1:1. The pH was adjusted to 9.0 
with 0.1N aqueous LiOH. ESR spectra were recorded with an X-band ESR spectrometer, JES-TE200, 
JEOL, Japan, at liquid nitrogen temperature (77K). Instrumental conditions for the ESR measurements 
were as fellows: Modulation frequency 100 kHz, modulation amplitude 0.63mT and microwave power 
1.45 mW. The g-values of the complexes were calibrated using Mn(II) in MgO (ΔH3-4 = 8.69 mT). The 
α2-value for Cu(II) complexes was calculated from ESR parameters using the equation of Kivelson and 
Neiman (α2=A･/P+(g-2.0023)+3/7(g⊥-2.0023)+0.04, P=360cm-1 
ESR spin trapping 
To a mixture of a solution of N-tert-butyl-α-phenylnitrone in ethanol (250μL) and potassium phosphate 
buffer (50mM, pH 7.0, 500μL) were added a solution of ligand and iron(II) tetrafluoroborate hexahydrate 
 in ethanol (500μL) under fully deaerated condition. The whole thing was mixed well in aerobic condition 
and ESR spectra were measured at room temperature. Instrumental conditions for the ESR measurements 
were as fellows: Modulation frequency 100kHz, modulation amplitude 0.32×10-1mT and microwave 
power 1.00mW. 
DNA cleavage assay 
A solution of purified pUC19 DNA (2μL of a stock solution containing ca. 260μg mL-1) was incubated at 
37°C for 60 min with ligand and FeSO4•H2O in methanol solution (4μL of each concentration of stock 
solution), Tris borate buffer, pH 8.1 (4μL of a 20mM stock solution), H2O2 (2μL of 20mM stock solution) 
(complemented to give a total volume of 12μL). The mixture was quenched with EDTA and loading 
buffer (TaKaRa) and the DNA resolved by electrophoresis (Mupid-21)(100V, 1 h) on a 1.0% agarose gel 
(containing ethidium bromide) in Tris/Boronic acid/EDTA buffer. The bands detected by UV were 
analyzed and process using densitometer (AE-6900M, ATTO). 
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